Cisplatin-based chemotherapy in advanced seminoma: Experience of the Northern Israel Oncology Center: 1981–1994
✍ Scribed by Stein, Moshe E.; Kuten, Abraham; Drumea, Keren; Moshkowitz, Boaz; Nativ, Ofer; Munichor, Mariane; Haim, Nissim
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 90 KB
- Volume
- 64
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
The efficacy of cisplatinum combined chemotherapy modalities was investigated in a variety of trials for patients with advanced seminoma. results regarding remission rates and survival are encouraging.
Methods:
Between december 1981 and january 1994, 13 patients with either relapsed (following radiotherapy failure) or primarily advanced seminoma were treated with cisplatin-based chemotherapy at the northern israel oncology center.
Results:
Eleven (84%) patients achieved complete clearance of all sites of disease. one patient demonstrated clinically and radiographically remarkable shrinkage of an abdominal mass, and laparotomy revealed fibrotic/necrotic tissue without viable tumor cells. after a mean follow-up of 58 months (range 4-168), 12 patients (92%) are alive and well without evidence of malignancy. one patient, in whom a 2-cm abdominal mass is stable radiographically, is under observation with no sign of tumor activity. side effects were tolerable; no patient developed chemotherapy-induced sepsis. one patient developed spontaneous pneumothorax a few days after completion of his first chemotherapy cycle, which resolved with treatment.
Conclusions:
Our results confirm the efficacy and safety of cisplatin-based chemotherapy in the treatment of advanced seminoma, even in pre-irradiated patients.